ALK Positive

August 13, 2020

Newer targeted therapy prolongs life for lung cancer patients

Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study.

By Tom Wilemon
February 13, 2020

Advocacy group’s gift boosts lung cancer research efforts

An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.

By Tom Wilemon
June 14, 2018

Lung cancer patients and advocates visit VUMC research labs

A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.

By VUMC News and Communications